Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 6
2019 2
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Health Care Resource Use Among Patients with Advanced Non-Small Cell Lung Cancer in Japan, 2017-2019.
Goto Y, Kawamura K, Fukuhara T, Namba Y, Aoe K, Shukuya T, Tsuda T, Santorelli ML, Taniguchi K, Kamitani T, Irisawa M, Kanda K, Abe M, Burke T, Nokihara H. Goto Y, et al. Among authors: santorelli ml. Curr Ther Res Clin Exp. 2023 Jul 3;99:100712. doi: 10.1016/j.curtheres.2023.100712. eCollection 2023. Curr Ther Res Clin Exp. 2023. PMID: 37519418 Free PMC article.
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC.
Kim HR, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC, Mazieres J, Orlandi FJ, Luft A, Gümüş M, Kato T, Kalemkerian GP, Luo Y, Santorelli ML, Pietanza MC, Rudin CM. Kim HR, et al. Among authors: santorelli ml. JTO Clin Res Rep. 2023 Sep 9;4(11):100572. doi: 10.1016/j.jtocrr.2023.100572. eCollection 2023 Nov. JTO Clin Res Rep. 2023. PMID: 37954964 Free PMC article.
Real-World Treatments and Clinical Outcomes in Advanced NSCLC without Actionable Mutations after Introduction of Immunotherapy in Japan.
Nokihara H, Kijima T, Yokoyama T, Kagamu H, Suzuki T, Mori M, Santorelli ML, Taniguchi K, Kamitani T, Irisawa M, Kanda K, Abe M, Burke T, Goto Y. Nokihara H, et al. Among authors: santorelli ml. Cancers (Basel). 2022 Jun 9;14(12):2846. doi: 10.3390/cancers14122846. Cancers (Basel). 2022. PMID: 35740512 Free PMC article.
First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan.
Goto Y, Tamura A, Matsumoto H, Isobe K, Ozaki T, Santorelli ML, Taniguchi K, Kamitani T, Irisawa M, Kanda K, Abe M, Burke T, Nokihara H. Goto Y, et al. Among authors: santorelli ml. JTO Clin Res Rep. 2022 Aug 5;3(9):100397. doi: 10.1016/j.jtocrr.2022.100397. eCollection 2022 Sep. JTO Clin Res Rep. 2022. PMID: 36065450 Free PMC article.
15 results